Shares of Aclaris Therapeutics were trading higher after the company said regulators had cleared its new drug application for a trial of ATI-052, its potential treatment for immuno-inflammatory ...

I am excited to update you on our overall strategy, progress, and key priorities and goals for 2025. Strategic Overview and ...

With aircraft increasingly targeted by GPS jammers, the search for new ways to navigate is hotting up.

CsA Ophthalmic Gel is an innovative cyclosporine gel being developed by Zhaoke in China for the treatment of moderate to ...

Aclaris Therapeutics (NASDAQ:ACRS) said on Tuesday that the U.S. FDA has cleared its investigational new drug application to ...

Australia also utilises the Clinical Trial Exemption (CTX) scheme. The CTX scheme involves the sponsors submitting an application to conduct one or more clinical trials with a particular ...

Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, announced that the European Medicines Agency (EMA) approved the company’s Clinical ...

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up ...

has approved its Clinical Trial Application (CTA) for the drug candidate CLN-978. The Phase 1 clinical trial, slated to begin in Q2 2025, will evaluate the safety and efficacy of CLN-978 in ...

A rice-sized microrobot offers precision in brain surgery, starting with tumor biopsies in a first clinical trial set for ...

Genesis has gained US Food and Drug Administration (FDA) clearance on an Investigational New Drug (IND) application for a ...